← Back to Calendar

Bicycle Therapeutics Q4 2025 Earnings

Bicycle Therapeutics · $BCYC
Standard Review Earnings
Catalyst Date
March 10, 2026
Date Status
34d ago (past)
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$4.94 -24.35%
$-1.59 today
Day: $4.87 – $5.01
Market Cap
N/A
Shares out: 50.27M
52-Week Range
$4.24
$9.55
Current price is at 13% of 52-week range
Avg Volume
444K
Beta
1.65
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $BCYC catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q4 2025 earnings + BT8009 DUET-2 update

Key Notes

Q4 2025 earnings reported March 10, 2026. Update on BT8009 DUET-2 Phase 2 trial in metastatic urothelial carcinoma — data expected Q3 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar